Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY. The company's Chief Medical Officer, Dr. Dominic Smethurst, will be part of a panel discussion titled 'Capitalizing on Validated Mechanism in Oncology' at 1:30 pm ET.

Additionally, Dr. Smethurst and Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, will be available for one-on-one investor meetings during the event. Interested parties are advised to contact their BMO Capital Markets sales representative for registration details.

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York City. The company's CEO, Yuval Cohen, Ph.D., will be presenting at the event.

Key details of the presentation include:

• Date: September 17, 2024
• Time: 8:00 AM Eastern Time
• Location: InterContinental New York Barclay Hotel
• Format: Fireside chat with Cantor analyst Prakhar Agrawal

Dr. Cohen will also be available for one-on-one investor meetings during the conference. A webcast link for the presentation has been provided for those unable to attend in person.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Winston Kung to its Board of Directors, effective August 16, 2024. Mr. Kung, who will also chair the Audit Committee, brings over 20 years of leadership experience in life sciences and investment banking. Currently serving as CFO of Arrivent BioPharma, he has held senior positions at PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, and Amgen.

The company's leadership expressed enthusiasm for Mr. Kung's expertise in pharma industry and capital markets, viewing his appointment as valuable for advancing Corbus' pipeline. Simultaneously, Avery "Chip" Catlin has resigned from the Board and as Audit Committee Chair after serving for over ten years.

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. CRB-701: Encouraging Phase 1 data presented at ASCO 2024, showing 44% ORR in metastatic urothelial cancer and 43% ORR in cervical cancer. Phase 1 dose escalation underway in USA and Europe.

2. CRB-913: Phase 1 study for obesity treatment expected to commence in Q1 2025.

3. CRB-601: FDA cleared IND, Phase 1 study expected to initiate in Q4 2024.

4. Financial Results: Net loss of $10.0 million for Q2 2024. Cash, cash equivalents, and investments of $147 million as of June 30, 2024, expected to fund operations through Q3 2027.

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in two upcoming investor conferences in August 2024. CEO Yuval Cohen, Ph.D., will provide corporate updates and engage in investor meetings at these events:

1. BTIG Virtual Biotechnology Conference (August 5-6, 2024): Invitation-only, one-on-one investor meetings.

2. Wedbush PacGrow Healthcare Conference (August 13-14, 2024): Invitation-only, one-on-one and small group investor meetings.

Interested investors should contact their respective BTIG or Wedbush representatives to arrange meetings with Corbus management during these conferences.

Corbus Pharmaceuticals announced promising clinical data for SYS6002 (CRB-701), a Nectin-4 targeting antibody drug conjugate, during the ASCO 2024 conference.

The Phase 1 trial has enrolled 37 patients since January 2024, with 25 evaluated for efficacy. SYS6002 showed a 44% ORR and 78% DCR in metastatic urothelial cancer (mUC), and a 43% ORR and 86% DCR in cervical cancer at doses ≥ 1.2 mg/Kg.

No dose-limiting toxicities were observed up to 4.5 mg/Kg. Notable adverse events included three cases of skin rash and one instance of grade 1 neuropathy, all resolved. Pharmacokinetic data demonstrated lower free MMAE levels than enfortumab vedotin across all doses.

The trial continues to show SYS6002's safety and efficacy, with the U.S. clinical study expected to complete in Q4 2024, with data presentation in Q1 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update at the 45th Annual Goldman Sachs Global Healthcare Conference in Miami Beach, FL, from June 10-13, 2024. The presentation is scheduled for June 12, 2024, at 2:40 p.m. ET. Investors will have the opportunity to participate in one-on-one meetings with the CEO. The presentation will be webcast.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that an abstract titled 'Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701)' will be presented at the 2024 ASCO Annual Meeting. This presentation will occur on June 1, 2024, and will provide updated clinical data from a Phase 1 trial. The trial involves dose escalation spanning seven levels and employs a Bayesian Optimal Interval design. The study aims to establish the Maximum Tolerated Dose (MTD) and Phase 2 dose for SYS6002 (CRB-701) in patients with advanced solid tumors unresponsive to standard treatments. Key findings include safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The study is conducted in China by Corbus's partner CSPC, with a parallel Phase 1 study recently initiated in the U.S., where the first patient was dosed in April 2024.

Corbus Pharmaceuticals Holdings, Inc. will partake in the 2024 RBC Capital Markets Global Healthcare Conference. Yuval Cohen, the CEO, will engage in a fireside chat and investor meetings on May 14-15, 2024, in New York. The event will include a webcast on May 14 at 9:30 a.m. ET.